Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.


Listen to the latest hemonc news from international experts

Myeloma treatment updates from EHA 2022

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.

In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in myeloma treatment from this year’s EHA meeting, drawing focus on the DETERMINATION trial (NCT01208662) and the promise of novel immunotherapies.

Date: 3rd August 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter